Evolve Biotherapeutics
Oncolytic virus immunotherapy for treatment-resistant cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
JPY180m | Late VC | ||
| Total Funding | 000k | ||
Evolve Biotherapeutics is a Japanese biopharmaceutical company focused on developing novel cancer treatments. The firm is advancing research on a cancer-treating vaccinia virus originally developed at Tottori University. This oncolytic virus immunotherapy aims to treat cancers that are resistant to current therapies by using a virus to dissolve tumors without surgery. The company's mission is to eradicate cancer and restore smiles to people around the world.
The company is a tenant at the Tottori Bio Frontier (TBF) facility, which supports biotech startups with research facilities, business advice, and funding access. The development of its new cancer virotherapy drug is being advanced with the goal of delivering it to patients as quickly as possible.
Keywords: oncolytic virus, virotherapy, cancer treatment, immunotherapy, vaccinia virus, treatment-resistant cancer, biopharmaceutical, Tottori University, drug development, cancer research